Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
Poster presentation at AACR Special Conference on Pancreatic Cancer
Amplia appoints new CFO
ACCENT Trial Recruitment Update
Quarterly Activities and Cash Flow Report - 30 June 2023
Investor Newsletter July 2023
Archives
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
Categories
Company News
Media
Uncategorized
Videos
September 30th, 2021
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
Read More
September 30th, 2021
Breakthrough research lowers pancreatic cancer’s resistance to chemo
Read More
September 30th, 2021
New FAK research published in Science Advances
Read More
September 29th, 2021
VIDEO | Proactive Lifesciences Webinar
Read More
September 27th, 2021
Proactive Lifesciences Webinar
Read More
September 22nd, 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
September 20th, 2021
Proactive | Interview with Dr John Lambert
Read More
July 26th, 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
July 26th, 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
July 21st, 2021
Amplia Therapeutics returns successful phase one trial results
Read More
July 19th, 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
June 30th, 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
June 28th, 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
June 2nd, 2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
Read More
March 18th, 2021
Amplia Therapeutics signs agreement with Garvan Institute
Read More
March 17th, 2021
Amplia Therapeutics completes single-dose study of AMP945
Read More
October 14th, 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
October 9th, 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
October 9th, 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
2
3
4
